Ovarian Cancer: A New Hope for Survival
A deadly disease with vague symptoms, ovarian cancer has long been a challenging battle for many. The National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) program predicts a grim reality for 2025, with over 20,000 diagnoses and more than half of those cases spreading to distant organs. But there's a glimmer of hope on the horizon.
Dr. Hua-Ying Fan, a professor at The University of New Mexico's School of Medicine, has dedicated her research to finding a solution. Her work, published in Cancer Research Communications, offers a potential breakthrough.
The current chemotherapy treatment for ovarian cancer, involving carboplatin, cisplatin, and paclitaxel, has its limitations. While it initially shows promise, with over 80% of advanced cases responding, the cancer often returns, leaving patients with a median survival rate of just 18 months.
But here's where it gets controversial... Dr. Fan's research focuses on a specific pathway, known as the Notch pathway, which is crucial for the survival of certain ovarian cancer cells. These cells, called OVCAR3, are resistant to platinum-based chemotherapy, and Dr. Fan believes she has found a way to disrupt this pathway.
Enter auranofin, an FDA-approved drug for rheumatoid arthritis. Dr. Fan's study, "Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer," demonstrates that auranofin can effectively target the Notch pathway. In experiments, when auranofin and cisplatin were combined, a significant number of OVCAR3 cells died.
To further validate her findings, Dr. Fan collaborated with experts across various disciplines. Dr. Mara Steinkamp, an associate professor at UNM, and Dr. Kimberly Leslie, a research professor, joined forces to study the drug combination's effects on organoids and animal models. The results were promising: higher doses of the drug combination led to increased cancer cell death, and animals treated with the drugs lived longer with smaller tumors.
And this is the part most people miss... Dr. Fan emphasizes the importance of collaboration and the need for further studies. While the initial results are encouraging, not all ovarian cancer patients may benefit from this discovery due to the disease's variability. However, Dr. Fan remains optimistic, believing that future research will uncover potential benefits for many patients, potentially extending their lives beyond the current median survival rate.
The University of New Mexico Comprehensive Cancer Center, a leading institution in cancer research and treatment, stands at the forefront of this battle. With a team of over 136 board-certified oncology specialists and a dedicated research arm, they provide hope and treatment to thousands of cancer patients across New Mexico.
Dr. Fan's research is a testament to the power of scientific collaboration and innovation. While there's still a long road ahead, this discovery offers a ray of light in the fight against ovarian cancer.
Will this new treatment option revolutionize ovarian cancer care? Only time and further research will tell. But for now, we can celebrate the progress and the dedicated scientists who work tirelessly to improve survival rates and give hope to those affected by this devastating disease.
